ZM-H1505R

DRUG3 trials

Sponsors

Shanghai Zhimeng Biopharma, Inc.

Conditions

Healthy VolunteersHepatitis B, Chronic

Phase 1

A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants

CompletedNCT04220801

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers

Start: 2020-02-17End: 2020-11-18Updated: 2021-04-28

A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

CompletedNCT05470829

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers, Hepatitis B, Chronic

Start: 2021-05-27End: 2021-11-17Updated: 2022-07-22

Phase 2

A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB

Shanghai Zhimeng Biopharma, Inc.Hepatitis B, Chronic

Start: 2022-11-11End: 2024-12-30Target: 90Updated: 2023-05-08

Related Papers

Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

BMC Medicine2023-03-1617 citations

Safety, Tolerability, and Pharmacokinetics of a Novel Human Hepatitis B Virus Capsid Assembly Modulator Canocapavir: A Randomized First-in-Human Study.

2023-01-072 citations